MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

CTI BioPharma Corp Company Profile (NASDAQ:CTIC)

Consensus Ratings for CTI BioPharma Corp (NASDAQ:CTIC) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.81 (389.19% upside)

Analysts' Ratings History for CTI BioPharma Corp (NASDAQ:CTIC)
Show:
DateFirmActionRatingPrice TargetActions
2/10/2016Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016WallachBeth CapitalDowngradeHold -> SellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016Piper JaffrayDowngradeOverweight -> Neutral$4.00 -> $0.75View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016S&P Equity ResearchLower Price Target$0.48 -> $0.39View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015Roth CapitalReiterated RatingBuy$4.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015Janney Montgomery ScottReiterated RatingBuy -> Fair Value$3.50 -> $1.94View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2015HC WainwrightReiterated RatingBuy$6.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for CTI BioPharma Corp (NASDAQ:CTIC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/10/2016Q1($0.04)$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2016Q4($0.18)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.12)($0.19)$18.89 million$1.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.10)($0.19)$12.77 million$1.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.14)($0.16)$9.84 million$2.73 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.18)($0.27)$2.48 million$17.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2014Q3$0.03$0.03ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014Q2($0.12)($0.19)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2014Q114($0.17)($0.20)$1.10 million$1.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2014Q4($0.16)$0.08$1.26 million$32.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2013Q4 2012($0.20)($0.20)$1.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for CTI BioPharma Corp (NASDAQ:CTIC)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for CTI BioPharma Corp (NASDAQ:CTIC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for CTI BioPharma Corp (NASDAQ:CTIC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/24/2016James A BiancoCEOSell10,000$0.37$3,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2016James A BiancoCEOSell10,000$0.45$4,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2016James A BiancoCEOSell10,000$0.52$5,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2016James A BiancoCEOSell10,000$0.49$4,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016James A BiancoCEOSell318,169$0.55$174,992.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Matthew PlunkettEVPSell10,000$0.59$5,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Jack W SingerEVPSell15,000$0.63$9,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016James A BiancoCEOSell10,000$0.63$6,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016James A BiancoCEOSell100,000$0.42$42,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2016Matthew PlunkettEVPSell10,000$1.15$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016Jack W. SingerEVPSell15,000$1.18$17,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016James A BiancoCEOSell10,000$1.20$12,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2016Value Fund L P BiotechnologyInsiderBuy1,001,327$1.22$1,221,618.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Matthew PlunkettEVPSell10,000$1.21$12,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2015James A. BiancoCEOSell110,000$1.26$138,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015James A. BiancoCEOSell10,000$1.29$12,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2015Jack W. SingerEVPSell15,000$1.18$17,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Matthew PlunkettEVPSell10,000$1.00$10,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Jack W. SingerEVPSell15,000$1.21$18,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015James A BiancoCEOSell10,000$1.23$12,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Louis A. BiancoEVPSell15,000$1.13$16,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2015James A BiancoCEOSell260,000$1.35$351,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2015Louis A. BiancoEVPSell10,000$1.41$14,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2015Jack W. SingerEVPSell15,000$1.62$24,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2015Louis A BiancoEVPSell10,000$1.58$15,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Matthew PlunkettEVPSell10,000$1.52$15,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015Jack W. SingerEVPSell100,000$1.42$142,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015James A. BiancoCEOSell600,000$1.43$858,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015Richard L. LoveDirectorSell13,660$1.45$19,807.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2015Louis A. BiancoEVPSell170,000$1.41$239,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Jack W. SingerEVPSell15,000$1.64$24,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2015Matthew PlunkettEVPSell75,869$1.57$119,114.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2015Matthew PlunkettEVPSell10,000$1.54$15,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Jack W. SingerEVPSell15,000$1.58$23,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/24/2015Jack W SingerEVPSell15,000$1.91$28,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2015Louis A BiancoEVPSell10,000$1.91$19,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Matthew PlunkettEVPSell10,000$1.95$19,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015Jack W SingerEVPSell15,000$2.07$31,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Louis A BiancoEVPSell10,000$2.18$21,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015Matthew PlunkettEVPSell10,000$2.06$20,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Jack W SingerEVPSell15,000$1.74$26,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2015Louis A BiancoEVPSell10,000$1.80$18,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2015Matthew PlunkettEVPSell10,000$1.86$18,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2015Jack W SingerEVPSell15,000$1.96$29,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015Louis A BiancoEVPSell10,000$1.93$19,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2015Matthew PlunkettEVPSell16,569$1.88$31,149.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015James A BiancoCEOSell175,199$1.95$341,638.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Matthew PlunkettEVPSell59,130$1.96$115,894.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Louis A BiancoEVPSell63,000$1.94$122,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2015Jack W SingerEVPSell15,000$2.35$35,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2015Louis A BiancoEVPSell10,000$2.22$22,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Matthew PlunkettEVPSell12,000$2.22$26,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Louis A BiancoEVPSell10,000$2.32$23,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Matthew PlunkettEVPSell12,000$2.36$28,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2014James A BiancoCEOSell40,000$2.44$97,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2014Louis A BiancoEVPSell10,000$2.25$22,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2014Louis A BiancoEVPSell10,000$2.37$23,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2014Matthew PlunkettEVPSell12,000$2.39$28,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2014Matthew PlunkettEVPSell103,635$2.56$265,305.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014James A BiancoCEOSell307,068$2.53$776,882.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Matthew PlunkettEVPSell51,817$2.58$133,687.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2014Louis A BiancoEVPSell145,000$2.59$375,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014Matthew PlunkettEVPSell27,301$2.48$67,706.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014James A BiancoCEOSell40,000$2.54$101,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/4/2014Matthew PlunkettEVPSell12,000$2.48$29,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Louis A BiancoEVPSell10,000$2.73$27,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Matthew PlunkettEVPSell12,000$2.89$34,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2014James A BiancoCEOSell50,000$2.84$142,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2014Louis A BiancoEVPSell10,000$2.97$29,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Louis BiancoEVPSell10,000$2.91$29,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2014Vartan GregorianDirectorSell82,000$3.41$279,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Phillip Phd NudelmanDirectorSell100,000$3.56$356,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2014Jack SingerEVPSell60,000$3.47$208,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014James BiancoCEOSell395,000$3.83$1,512,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Matthew PlunkettEVPSell170,000$3.73$634,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2014Fred TellingDirectorSell72,095$3.75$270,356.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2013James A BiancoCEOSell130,551$1.50$195,826.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013James A BiancoCEOSell25,925$1.08$27,999.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2013James A BiancoCEOSell40,000$1.07$42,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2013Mary Oneil MundingerDirectorSell125,000$1.06$132,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2013Phillip M Phd NudelmanDirectorSell50,000$1.09$54,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/26/2013James A BiancoCEOSell25,688$1.09$27,999.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013James A BiancoCEOSell26,053$1.08$28,137.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Jack W SingerEVPSell10,000$1.26$12,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013James A BiancoCEOSell28,000$1.22$34,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013Louis A BiancoEVPSell33,712$1.24$41,802.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2013Fred TellingDirectorSell64,798$1.24$80,349.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2013Richard L LoveDirectorSell23,000$1.21$27,830.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013James A BiancoCEOSell25,000$1.16$29,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2013Louis A BiancoEVPSell50,000$1.15$57,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2013Jack W SingerEVPSell13,000$1.28$16,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/10/2012James A BiancoCEOSell10,000$0.42$4,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for CTI BioPharma Corp (NASDAQ:CTIC)
DateHeadline
06/25/16 03:20 PMCTI BioPharma Corp. (NASDAQ:CTIC): Update on Stock Performance - Press Telegraph
06/25/16 07:19 AMCTI BioPharma Corp. (CTIC) is Trading Lower on Unusual Volume for June 22 - Equities.com
06/23/16 08:24 PMCTI BioPharma Corp. (NASDAQ:CTIC): Share Update and Performance Review - Press Telegraph
06/23/16 08:24 PMChecking in on Consensus Views for CTI BioPharma Corp. (NASDAQ:CTIC) - Press Telegraph
06/17/16 03:19 PMLast Traded Price Fluctuations: CTI BioPharma Corp. (NASDAQ:CTIC) , Press Ganey Holdings, Inc. (NYSE:PGND) - Street Updates
06/13/16 03:17 PMComprehensive Analysis of: Companhia Paranaense de Energia - COPEL (NYSE:ELP), CTI BioPharma Corp ... - Beacon Chronicle
06/10/16 03:33 PMSurging Earnings Estimates Signal Good News for CTI BioPharma (CTIC) - Nasdaq
06/10/16 07:32 AMSurging Earnings Estimates Signal Good News for CTI BioPharma (CTIC) -
06/08/16 07:08 AMShould CTI BioPharma (CTIC) Be On Your Radar Now? -
06/07/16 11:34 AMCompany Update (NASDAQ:CTIC): CTI BioPharma Corp Presented Long-Term Follow Up Data For Pacritinib At 2016 ... - Smarter Analyst
06/07/16 02:17 AM3:17 am CTI BioPharma presents LT follow up data for Pacritinib showing reductions in spleen volume and symptom burden -
06/07/16 12:30 AMLong-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting - [PR Newswire] - SEATTLE, June 7, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced long-term safety and efficacy results from the pivotal Phase 3 PERSIST-1 trial evaluating pacritinib versus best available therapy, excluding treatment with JAK2 inhibitors (BAT), in patients with myelofibrosis. The results represent an update on the efficacy and safety for all patients regardless of their initial platelet count, including patients with very low platelet counts at study entry, a condition known as severe or life-threatening thrombocytopenia. A planned analysis of the study up to 72 weeks demonstrated treatment with pacritinib led to durable reductions in spleen volume and symptom burden, two key measures of disease control, in patients with myelofibrosis, including patients with low platelets at baseline (less than 50,000 per microliter and less than 100,000 per microliter).
06/06/16 08:53 PMAnalyst Recommended These Stocks to Buy: CTI BioPharma Corp. (NASDAQ:CTIC), Accenture plc (NYSE:ACN) - Beacon Chronicle
06/06/16 03:19 PMCTI BIOPHARMA CORP. (NASDAQ:CTIC) Financial Condition Compared to S&P 500 - CML News
06/06/16 05:32 AMCti Biopharma Corporation (NASDAQ:CTIC) Shorted Shares Increased 5.14% After Market Selling - HNN
06/03/16 02:15 PMETF’s with exposure to CTI BioPharma Corp. : June 3, 2016 -
06/03/16 10:58 AMSentiment Score Update: CTI BioPharma Corp. (NASDAQ:CTIC) - HNN
06/02/16 03:34 PMTarget Price Outlook on CTI BioPharma Corp. (NASDAQ:CTIC) - HNN - Target Price Outlook on CTI BioPharma Corp. (NASDAQ:CTIC)HNNEquity analysts that track CTI BioPharma Corp. (NASDAQ:CTIC) shares have provided targets on where they believe the stock will move in the future. The present consensus target price compiled using analysts polled by Zacks Research sits at $2.875.and more »
06/01/16 10:41 AMAnalysts Observing Stocks Update: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , CTI BioPharma Corp ... - Street Updates - Analysts Observing Stocks Update: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , CTI BioPharma Corp ...Street UpdatesHowever, 6 analysts recommended “HOLD RATING” for the company. “UNDERPERFORM RATING” issued by 0 analysts and “SELL RATING” signal was suggested by 0 analysts. In the past trading session, CTI BioPharma Corp. (NASDAQ:CTIC) highlighted ...and more »
05/31/16 09:11 PMStock Performance Check on : CTI BioPharma Corp. (NASDAQ:CTIC) - HNN - Stock Performance Check on : CTI BioPharma Corp. (NASDAQ:CTIC)HNNTracking share activity in recent trading action, shares of CTI BioPharma Corp. have been recorded 82.98% away from the 52 week low. Company shares have been recently seen -81.30% off of the 52 week high. The stock has been trading at 15.03% ...
05/31/16 03:31 PMCTI BioPharma Corp. (NASDAQ:CTIC) Stock Update & Estimates - Stock Tick Tock - CTI BioPharma Corp. (NASDAQ:CTIC) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting CTI BioPharma Corp. (NASDAQ:CTIC) to post earnings of $-0.09 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued ...and more »
05/30/16 04:26 PMStock Performance Review : CTI BioPharma Corp. (NASDAQ:CTIC) - HNN - Stock Performance Review : CTI BioPharma Corp. (NASDAQ:CTIC)HNNShares of CTI BioPharma Corp.(NASDAQ:CTIC) have been recently seen at -81.37% away from the 52 week high and 82.34% separated from the 52 week low. If we move in a bit closer, the stock has been recently recorded at -20.97% away from the 50 day ...and more »
05/29/16 04:11 PMPerformance at a Glance on CTI BioPharma Corp. (NASDAQ:CTIC) - HNN - Performance at a Glance on CTI BioPharma Corp. (NASDAQ:CTIC)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how CTI BioPharma Corp. (NASDAQ:CTIC)'s stock has performed at various points in its past. Currently, the ...Cti Biopharma Corp (CTIC) Files Form 4 Insider Selling : James A Bianco Sells 10000 SharesMarket Digestall 8 news articles »
05/28/16 02:54 AMCti Biopharma Corporation (NASDAQ:CTIC) Sellers Increased By 5.14% Their Shorts - HNN - Cti Biopharma Corporation (NASDAQ:CTIC) Sellers Increased By 5.14% Their ShortsHNNThe stock of Cti Biopharma Corporation (NASDAQ:CTIC) registered an increase of 5.14% in short interest. CTIC's total short interest was 12.72 million shares in May as published by FINRA. Its up 5.14% from 12.09M shares, reported previously. With 1.18M ...and more »
05/27/16 04:39 PMActive Stock Rundown: CTI BioPharma Corp. (NASDAQ:CTIC) - Wall Street Hints and News - Active Stock Rundown: CTI BioPharma Corp. (NASDAQ:CTIC)Wall Street Hints and NewsShare activity for CTI BioPharma Corp.(NASDAQ:CTIC) lands shares on today's active list. Since the open, shares have moved -0.46% at the time of writing. Checking in on trading activity, the stock recently hit $0.45. Company stock has been recently ...and more »
05/27/16 04:39 PMCTI BioPharma Corp. (NASDAQ:CTIC) News Sentiment Review - Wall Street Hints and News - CTI BioPharma Corp. (NASDAQ:CTIC) News Sentiment ReviewWall Street Hints and NewsCTI BioPharma Corp. (NASDAQ:CTIC) has a present news sentiment score of -0.115. This score is given by Beta Research using a scale from 1 to -1. A 1 score may indicate positive news sentiment while a score of -1 may indicate the opposite.and more »
05/26/16 04:27 PMProjected Earnings Look at CTI BioPharma Corp. (NASDAQ:CTIC) - Wall Street Hints and News - Projected Earnings Look at CTI BioPharma Corp. (NASDAQ:CTIC)Wall Street Hints and NewsResearch firms closely tracking CTI BioPharma Corp. (NASDAQ:CTIC) shares are on a consensus basis projecting $-0.09 per share for the quarter. This number is provided by Zacks Research and it is the consensus number using polled analysts. Investors ...and more »
05/25/16 09:22 PMNotable Stocks Preview: CTI BioPharma Corp. (NASDAQ:CTIC) , Juno Therapeutics, Inc. (NASDAQ:JUNO) - Street Updates - Notable Stocks Preview: CTI BioPharma Corp. (NASDAQ:CTIC) , Juno Therapeutics, Inc. (NASDAQ:JUNO)Street UpdatesCTI BioPharma Corp. (NASDAQ:CTIC) diminished -0.51%, closing at $0.45 after floating between $0.43 and $0.46. The company has market capitalization of $125.07M. It has twelve month low of $0.25 and twelve month high of $2.46. The recent traded ...CTI BioPharma Corp. (NASDAQ:CTIC) - Company FocusFranklin IndependentCTI BioPharma Corp. (NASDAQ:CTIC) One-Year Price Target At $1.92Equities FocusInsiders Are Gradually Buying CTI BioPharma Corp. (NASDAQ:CTIC)Wall Street Hints and NewsNews Tribuneall 7 news articles »
05/24/16 04:24 PMCTI BioPharma Corp. (NASDAQ:CTIC) Quarterly EPS From Continuing Operations Stands At $0.0108 - Investor Newswire - CTI BioPharma Corp. (NASDAQ:CTIC) Quarterly EPS From Continuing Operations Stands At $0.0108Investor Newswire(NASDAQ:CTIC) diluted EPS from parent firm came at $-0.634 for the year ended 2016-03-31. For the quarter ended 2016-03-31 it came at $-0.634. CTI BioPharma Corp. (NASDAQ:CTIC) posted net basic EPS of $-0.65 for the year ended 2016-03-31. For the ...Analysts Say Hold on : CTI BioPharma Corp. (NASDAQ:CTIC)The Postall 2 news articles »
05/23/16 04:19 PMCTI BioPharma Corp. (NASDAQ:CTIC) Stock Impact Update - Wall Street Hints and News - CTI BioPharma Corp. (NASDAQ:CTIC) Stock Impact UpdateWall Street Hints and NewsStock traders might be interested in keeping tabs on news and sentiment scores across the internet. CTI BioPharma Corp. (NASDAQ:CTIC) has been given an impact score of 100. The impact score is offered to provide current insight on how the stock might ...and more »
05/23/16 04:19 PMCTI BioPharma Corp. (NASDAQ:CTIC) To Reach $2.875 - Stock Tick Tock - CTI BioPharma Corp. (NASDAQ:CTIC) To Reach $2.875Stock Tick TockThe Wall Street sell-side, who serve as intermediaries between stock issuers and investors, have a consensus target price of $2.875 on CTI BioPharma Corp. (NASDAQ:CTIC) shares. The most aggressive analyst target sees the stock reaching $5 within the ...and more »
05/23/16 09:07 AMTraders Spotlight: TherapeuticsMD, Inc. (NYSEMKT:TXMD) , CTI BioPharma Corp. (NASDAQ:CTIC) - Street Updates - Traders Spotlight: TherapeuticsMD, Inc. (NYSEMKT:TXMD) , CTI BioPharma Corp. (NASDAQ:CTIC)Street UpdatesOn 5/20/2016, TherapeuticsMD, Inc. (NYSEMKT:TXMD) ended trading session higher at $8.17 with +4.21%. The company traded a volume of 1.2 million shares as comparison to average volume of 1.38 million shares. During the 52 –week period, the stock's ...and more »
05/21/16 07:38 AMRevenue Update on CTI BioPharma Corp(NASDAQ:CTIC) - Trade Calls - Revenue Update on CTI BioPharma Corp(NASDAQ:CTIC)Trade CallsCTI BioPharma Corp(NASDAQ:CTIC) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 10, 2016. Company reported revenue of $36.48M. Analysts estimated a revenue of $20.91M. Earnings per ...and more »
05/20/16 04:17 PMStock Mover in Focus : CTI BioPharma Corp. (NASDAQ:CTIC) - Wall Street Hints and News - Stock Mover in Focus : CTI BioPharma Corp. (NASDAQ:CTIC)Wall Street Hints and NewsTrading activity of :CTI BioPharma Corp.(NASDAQ:CTIC) shares gets the stock on today's active list. As of this writing, the change from the opening price is 0.49%. After a recent check, the stock price had reached $0.45. Company shares are currently ...and more »
05/20/16 10:40 AMETF’s with exposure to CTI BioPharma Corp. : May 20, 2016 -
05/19/16 12:30 PMCTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/19/16 12:04 PMCTI BIOPHARMA CORP Financials -
05/19/16 12:30 AMCTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting - [PR Newswire] - SEATTLE, May 19, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced that data highlighting pacritinib, including additional safety and long-term follow up data from the ...
05/16/16 09:09 PMCTI BioPharma Corp. (NASDAQ:CTIC) Comprehensive Income At $-6.952 - RealistInvestor.com - CTI BioPharma Corp. (NASDAQ:CTIC) Comprehensive Income At $-6.952RealistInvestor.comFor the year ended 2015-12-31, CTI BioPharma Corp. (NASDAQ:CTIC)comprehensive income was $-6.952 millions whereas for the quarter ended 2015-12-31, it was $-6.952 millions. CTI BioPharma Corp. (NASDAQ:CTIC) posted $-120.763 millions on ...Investors Reviewing Stocks: Alkermes plc (NASDAQ:ALKS) , CTI BioPharma Corp. (NASDAQ:CTIC)Street UpdatesCTI BioPharma Corp. (NASDAQ:CTIC) - Shares in ReviewFranklin IndependentWhy Need to Watch: CTI BioPharma Corp. (NASDAQ:CTIC), Visa Inc. (NYSE:V), Salisbury Bancorp Inc. (NASDAQ:SAL ...KC Registerall 5 news articles »
05/16/16 09:09 PMHC Stocks Newsbeat: CTI BioPharma Corp (CTIC), MEI Pharma Inc (MEIP), Celldex Therapeutics, Inc. (CLDX) - share market updates (press release) - share market updates (press release)HC Stocks Newsbeat: CTI BioPharma Corp (CTIC), MEI Pharma Inc (MEIP), Celldex Therapeutics, Inc. (CLDX)share market updates (press release)Shares of CTI BioPharma Corp (NASDAQ:CTIC) ended Friday session in green amid volatile trading. The shares closed up +0.016 points or 3.76% at $0.447 with 546,042.00 shares getting traded. Post opening the session at $0.45, the shares hit an intraday ...and more »
05/14/16 09:18 PMCTI BioPharma Corp. (NASDAQ:CTIC) One-Year Mean Price Target At $0.75 - Investor Newswire - CTI BioPharma Corp. (NASDAQ:CTIC) One-Year Mean Price Target At $0.75Investor NewswireSell-side analysts are confident on the future outlook of CTI BioPharma Corp. (NASDAQ:CTIC) stock. As of 2016-05-13, the stock has an ABR of 3.67 rating, where number 5 denotes a Strong Sell and 1 Strong Buy. The ABR is reached on the basis of ...and more »
05/12/16 04:37 PMCTI BioPharma Corp. (NASDAQ:CTIC) Impact Report & Update - Wall Street Hints and News - CTI BioPharma Corp. (NASDAQ:CTIC) Impact Report & UpdateWall Street Hints and NewsRetail investors and institutions alike now have at their fingertips the ability to monitor impact and sentiment scores on a given stock. CTI BioPharma Corp. (NASDAQ:CTIC) has been given a recent stock impact score of 95. The impact score may help by ...and more »
05/11/16 09:52 PMResults of Operations and Financial Condition, Financial Statements and Exhibi - On May 10, 2016, CTI BioPharma Corp. issued a press release announcing its financial results for the quarter and year ended March 31, 2016 and certain other information. The full text of the press release is set forth in Exhibit 99.1 hereto.
04/28/16 04:02 PMCTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan -
04/20/16 12:30 AMPreclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment - [PR Newswire] - SEATTLE, April 20, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced findings from an investigator-sponsored preclinical study indicating that pacritinib, an inhibitor of JAK2, FLT3, IRAK1 and CSF1R, may be effective in reducing survival of myelofibrosis and acute myeloid leukemia (AML) repopulating cells. Further, this study also demonstrated that the combination of pacritinib at low nanomolar concentrations with dasatinib may eliminate self-renewing leukemia stem cells in blast crisis of chronic myeloid leukemia (CML) with minimal toxicity toward normal progenitors.
04/18/16 05:02 AMCTI BIOPHARMA CORP Files SEC form 8-K, Other Events -
04/13/16 12:30 AMCTI BioPharma Announces Presentations at the American Association of Cancer Research Annual Meeting - [PR Newswire] - SEATTLE, April 13, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced that data highlighting pacritinib, pixantrone and tosedostat will be presented at the upcoming American ...
04/08/16 05:30 PMSHAREHOLDER NOTICE: Rosen Law Firm Reminds CTI BioPharma Corp. Investors of Important April 11, 2016 Deadline in Class Action – CTIC - [GlobeNewswire] - NEW YORK, April 08, 2016-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of CTI BioPharma Corp. securities pursuant to and/or traceable to the Registration Statement and Prospectus ...
04/08/16 10:21 AMSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In CTI BioPharma Corp. To Contact The Firm Before Imminent Lead Plaintiff Deadline - [Accesswire] - NEW YORK, NY / ACCESSWIRE / April 8, 2016 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CTI BioPharma Corp. ("CTI" or the "Company") (NASDAQ: ...
04/08/16 09:00 AMDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against CTI BioPharma Corp. (CTIC) and Lead Plaintiff Deadline: April 11, 2016 - [Accesswire] - NEW YORK, NY / ACCESSWIRE / April 8, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors of class action against CTI BioPharma Corp. ("CTI" or the "Company") (NASDAQ: CTIC). ...
About CTI BioPharma Corp

CTI BioPharma Corp logoCTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CTIC
  • CUSIP:
Key Metrics:
  • Previous Close: $0.37
  • 50 Day Moving Average: $0.43
  • 200 Day Moving Average: $0.70
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $102.83M
  • Current Quarter EPS Consensus Estimate: $-0.25 EPS
Additional Links:
CTI BioPharma Corp (NASDAQ:CTIC) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha